(Q40384212)

20 September 2017

title

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations (English)

1 reference

20 September 2017

1 reference

10

1 reference

20 September 2017

Daniel G Tenen

11

0 references

Pasi A Jänne

13

object named as

Pasi A Jänne

1 reference

20 September 2017

Toru Mukohara

1

1 reference

20 September 2017

Jeffrey A Engelman

2

1 reference

20 September 2017

Nasser H Hanna

3

1 reference

20 September 2017

Beow Y Yeap

4

1 reference

20 September 2017

Susumu Kobayashi

5

1 reference

20 September 2017

Neal Lindeman

6

1 reference

20 September 2017

Balázs Halmos

7

1 reference

20 September 2017

Joseph Pearlberg

8

1 reference

20 September 2017

Zenta Tsuchihashi

9

1 reference

20 September 2017

Bruce E Johnson

12

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Journal of the National Cancer Institute

20 September 2017

published in

1 reference

20 September 2017

volume

97

1 reference

20 September 2017

issue

16

1 reference

20 September 2017

page(s)

1185-1194

1 reference

The EGF receptor family as targets for cancer therapy

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Somatic mutations of epidermal growth factor receptor in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI238

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJI238

1 reference

20 September 2017

1 reference